BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19172526)

  • 1. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
    Kanazawa S; Yamaguchi K; Kinoshita Y; Siomi K; Tujimoto M; Hanayama K; Sasada S; Hirashima T; Imamura F; Nomura S
    Platelets; 2009 Feb; 20(1):70-1. PubMed ID: 19172526
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin reduces adverse effects of gefitinib.
    Kanazawa S; Yamaguchi K; Kinoshita Y; Muramatsu M; Komiyama Y; Nomura S
    Anticancer Drugs; 2006 Apr; 17(4):423-7. PubMed ID: 16550000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
    Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
    Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
    Yalçin S; Dizdar O; Yalçin B; Gököz O
    J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
    [No Abstract]   [Full Text] [Related]  

  • 5. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
    Chiu HY; Cheng YP; Jee SH; Tsai TF
    Clin Exp Dermatol; 2012 Dec; 37(8):922-4. PubMed ID: 22731795
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
    Böker B; Lüders H; Grohé C
    Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
    Bidoli P; Cortinovis DL; Colombo I; Crippa A; Cicchiello F; Villa F; Cazzaniga ME; Altomare G
    J Thorac Oncol; 2010 Oct; 5(10):1662-3. PubMed ID: 20871265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular rash during therapy with erlotinib (Tarceva).
    Gerdes S; Mrowietz U
    J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
    Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
    J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?
    Dippel DW; Van Kooten F; Leebeek FW; van Vliet HH; Mehicevic A; Li SS; Koudstaal PJ
    Cerebrovasc Dis; 2004; 17(4):296-302. PubMed ID: 15026612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
    Fuchs I; Spiel AO; Frossard M; Derhaschnig U; Riedmüller E; Jilma B
    Crit Care Med; 2010 Jun; 38(6):1423-9. PubMed ID: 20400900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
    Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
    Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
    Würtz M; Grove EL; Kristensen SD; Hvas AM
    Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
    Lacouture ME; Hwang C; Marymont MH; Patel J
    J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
    [No Abstract]   [Full Text] [Related]  

  • 18. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
    Zhang PL; Chen L
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
    Lessiani G; Vazzana N; Cuccurullo C; Di Michele D; Laurora G; Sgrò G; Di Ruscio P; Simeone E; Di Iorio P; Lattanzio S; Liani R; Ferrante E; Davì G
    Thromb Haemost; 2011 Feb; 105(2):321-8. PubMed ID: 21103664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.